Contrast Agents and Radiopharmaceuticals | Market Insights | Europe | 2021
Because the COVID-19 pandemic is negatively affecting the overall volume of diagnostic imaging procedures, the pandemic will have a significant impact on the European contrast agent and radiopharmaceutical market in the short term. Once the situation improves, the European contrast agent and radiopharmaceutical market will resume slow growth through 2029, driven by rising radiopharmaceutical ASPs and increasing demand for diagnostic imaging procedures for Europe’s aging population, although the market will be hindered to some extent by stringent reimbursement regulations and the ongoing safety controversy surrounding GBCAs.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe across a 10-year period.
